Pancreatic adenocarcinoma — current trends in diagnosis and treatment

IF 0.3 Q4 ONCOLOGY Oncology in Clinical Practice Pub Date : 2023-05-24 DOI:10.5603/ocp.2023.0016
A. Gruszczyńska, Krzysztof Kowalik, K. Hetman, A. Modrzejewski
{"title":"Pancreatic adenocarcinoma — current trends in diagnosis and treatment","authors":"A. Gruszczyńska, Krzysztof Kowalik, K. Hetman, A. Modrzejewski","doi":"10.5603/ocp.2023.0016","DOIUrl":null,"url":null,"abstract":"Pancreatic cancer, despite significant medical advances, is still a significant clinical problem. This article focuses on discussing risk factors, diagnostic methods, and treatment options. These elements are crucial in making a prompt diagnosis and initiating treatment. On average, a physician in primary care sees a patient with undi - agnosed pancreatic cancer once every few years. Knowing the underlying symptoms and referring the patient to an appropriate center can significantly increase survival. Diagnostic methods include physical examination, numerous imaging techniques, and determination of tumor markers in serum. Surgical treatment combined with adjuvant chemotherapy is the only chance of cure for pancreatic cancer patients qualified for surgery. However, most patients experience tumor recurrence. When a tumor recurs, treatment for these patients and patients with unresectable disease is palliative chemotherapy. Numerous studies are currently underway to improve diagnostic and treatment methods.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"48 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology in Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/ocp.2023.0016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Pancreatic cancer, despite significant medical advances, is still a significant clinical problem. This article focuses on discussing risk factors, diagnostic methods, and treatment options. These elements are crucial in making a prompt diagnosis and initiating treatment. On average, a physician in primary care sees a patient with undi - agnosed pancreatic cancer once every few years. Knowing the underlying symptoms and referring the patient to an appropriate center can significantly increase survival. Diagnostic methods include physical examination, numerous imaging techniques, and determination of tumor markers in serum. Surgical treatment combined with adjuvant chemotherapy is the only chance of cure for pancreatic cancer patients qualified for surgery. However, most patients experience tumor recurrence. When a tumor recurs, treatment for these patients and patients with unresectable disease is palliative chemotherapy. Numerous studies are currently underway to improve diagnostic and treatment methods.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胰腺腺癌——诊断和治疗的最新趋势
尽管在医学上取得了重大进展,但胰腺癌仍然是一个重大的临床问题。本文主要讨论危险因素、诊断方法和治疗方案。这些因素对于及时诊断和开始治疗至关重要。平均而言,初级保健的医生每隔几年就会看到一个未经诊断的胰腺癌患者。了解潜在症状并将患者转介到适当的中心可以显著提高生存率。诊断方法包括体格检查、多种成像技术和血清中肿瘤标志物的测定。手术联合辅助化疗是满足手术条件的胰腺癌患者唯一的治愈机会。然而,大多数患者会出现肿瘤复发。当肿瘤复发时,对这些患者和无法切除的患者的治疗是姑息性化疗。目前正在进行许多研究以改进诊断和治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.90
自引率
20.00%
发文量
46
审稿时长
15 weeks
期刊最新文献
Immunochemotherapy in patients with non-squamous lung cancer Chemotherapy in patients with testicular germ-cell tumors and end-stage renal disease requiring hemodialysis: two case reports Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index as clinical predictive and prognostic markers in patients with advanced pancreatic cancer receiving gemcitabine monotherapy Systemic treatment in triple-negative breast cancer patients — standard and novel approaches Tumor heterogeneity and its impact on sotorasib response in a patient with non-small cell lung cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1